# Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)

> **NCT04567810** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 48 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** anti-SARS-CoV-2 IgY
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04567810
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-18
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567810, "Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04567810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*